The emerging role of nuclear factor kappa B in renal cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Renal cell carcinoma (RCC) is the most common and deadliest urologic cancer, often presenting as a highly metastatic disease.
• Despite advancements, metastatic RCC remains largely incurable, necessitating novel therapeutic targets.
• Von Hippel-Lindau (VHL) gene aberrations are a primary risk factor for RCC, particularly clear cell type.

Purpose of the Study:

• To review the molecular mechanisms of RCC.
• To elucidate the role of nuclear factor kappa B (NF-κB) in various carcinomas, including RCC.
• To establish the rationale for targeting NF-κB as a therapeutic strategy for metastatic RCC.

Main Methods:

• Literature review of RCC pathogenesis and molecular targets.
• Analysis of NF-κB signaling pathways in cancer biology.
• Examination of the VHL gene's regulatory role in NF-κB activity.

Main Results:

• NF-κB regulates key aspects of RCC biology, including apoptosis resistance, angiogenesis, and multi-drug resistance.
• Loss of VHL function leads to increased NF-κB expression and activity.
• Enhanced NF-κB signaling promotes drug resistance and epithelial-mesenchymal-transition in RCC.

Conclusions:

• NF-κB is a critical mediator of RCC progression and therapeutic resistance.
• Targeting NF-κB presents a viable strategy for developing more effective treatments for metastatic RCC.
• Understanding the VHL-NF-κB axis is crucial for advancing RCC therapy.